- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05926947
OXXYNEA® GS: Study for Glycaemia Management
September 11, 2023 updated by: Fytexia
Evaluation of Two Plant Formulations for the Management of Glycemia on Pre-diabetic Participants
The aim of this study is to develop a proof of concept establishing a causal relationship between glycemia improvement through combination of polyphenols-rich botanical extracts or polyphenols-rich botanical extracts associated with white kidney bean extract and chromimum picolinate + zinc bisglycinate with chronic supplementation.
Chronic glycemia improvement will be assessed by following the evolution of HbA1c, postprandial glucose and insulin kinetics, and questionnaires.
The study design is double blinded randomized with 3 arms and 29 volunteers per arm.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
87
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Julien Cases
- Phone Number: +33 467219098
- Email: jcases@fytexia.com
Study Locations
-
-
Murcia
-
Guadalupe, Murcia, Spain, 30107
- Recruiting
- UCAM Universidad Católica San Antonio de Murcia
-
Contact:
- Linda H Chung, PhD
-
Principal Investigator:
- Linda H Chung, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Fasting Plasma Glucose 100 - 125 mg/dL
- HbA1c: 5.7-6.5 %
- Both sexes
- Overweight BMI range (25-30 Kg/m2)
- Age: 20-50 years old
Exclusion Criteria:
- Metabolic/Chronical disease
- Menopausal women
- Being pregnant, breastfeeding or wanting to have a baby
- Former obese with a history of yoyo effect
- Have been involved in a weight loss program in the past 12 months or subjected to weight reduction surgery
- Having started or quit smoking, having a high alcohol consumption
- Have in the past been in a long-term antibiotherapy (1 month or more) and/or a regular antibiotherapy in the past 12 months
- Allergy to olive, blackcurrant, pomegranate, grapefruit, white kidney bean, or corn.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Micro crystalline cellulose
|
Experimental: Verum A
|
Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract
|
Experimental: Verum B
|
Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: 12 weeks
|
Evaluation of changes in the glycated haemoglobin measurements in comparison of the 3 groups
|
12 weeks
|
Post prandial glycemia
Time Frame: 12 weeks
|
Evaluation of changes in acute and chronic glycemia: Changes in the postprandial glucose measurements in comparison of the 3 groups after the standardized breakfast at baseline, 4th, 8th and 12th week.
|
12 weeks
|
Post prandial insulemia
Time Frame: 12 weeks
|
Evaluation of changes in acute glycemia: Change in postprandial insulin in comparison of the 3 groups after the standardized breakfast at baseline, 4th, 8th and 12th week.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body weight
Time Frame: 12 weeks
|
Change in the body weight measurements in comparison of the 3 groups
|
12 weeks
|
Dual-energy X-ray (DEXA)
Time Frame: 12 weeks
|
Evaluation of changes in fat mass and lean mass using a Dual-energy X-ray absorptiometry and compare amongst 3 groups
|
12 weeks
|
Magnetic resonance imaging (MRI)
Time Frame: 12 weeks
|
Evaluation of changes in various fat layers (visceral, subcutaneous and deep subcutaneous) using a MRI and compare amongst 3 groups
|
12 weeks
|
Short Form 12 (SF-12) questionnaire
Time Frame: 12 weeks
|
Evaluation of changes in responses to SF-12 questionnaire.
SF-12 questionnaire is a health related questionnaire with 12 questions.
The total score range from 0-100, with higher score indicating better health status.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pedro Alcaraz, UCAM (Universidad Catolica San Antonio de Murcia)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 5, 2023
Primary Completion (Estimated)
June 10, 2025
Study Completion (Estimated)
December 10, 2025
Study Registration Dates
First Submitted
April 20, 2023
First Submitted That Met QC Criteria
June 29, 2023
First Posted (Actual)
July 3, 2023
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 11, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLYCOXY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Children's Hospital Los AngelesUniversity of Southern California; Tufts Medical CenterActive, not recruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
National Taiwan University HospitalCompleted
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
University of California, San FranciscoNational Institutes of Health (NIH)CompletedModerately Overweight IndividualsUnited States
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
Clinical Trials on Verum A
-
FytexiaCompleted
-
FytexiaCompletedHyperglycemia, PostprandialSpain
-
Merz Pharmaceuticals GmbHCompletedNystagmus, Acquired | Nystagmus, Congenital IdiopathicUnited Kingdom
-
Wuerzburg University HospitalUniversity of WuerzburgCompleted
-
BionovBioFortisCompleted
-
West China HospitalWest China Fourth Hospital, Sichuan UniversityRecruitingRadiotherapy; Complications | Malignant Tumor of Head and/or NeckChina
-
University of ZurichSwiss National Science Foundation; Rehab Basel; Clinique Romande de Readaptation and other collaboratorsRecruitingSpinal Cord Injury, AcuteSwitzerland
-
Wuerzburg University HospitalCompleted
-
Indonesia UniversityNot yet recruitingCancer | Nasopharyngeal Carcinoma | Mucositis
-
Shanghai Institute of Acupuncture, Moxibustion...Eye & ENT Hospital of Fudan University; Shanghai Eye Disease Prevention and...Recruiting